Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that it will host a virtual presentation on Wednesday, September 23, 2026, at 4:30 p.m. ET.
The presentation will provide an overview of the ARCT-810 Phase 2 clinical program for Ornithine transcarbamylase (OTC) deficiency and Arcturus’ mRNA liver therapeutics platform. Prior to the call, the Company will issue a press release summarizing the presentation.
Marshall Summar, M.D., Former founding member and Executive Committee member of the NIH UCD Consortium, a recognized expert in rare diseases and OTC deficiency, will participate in the presentation.
- Previously Chief of the Division of Genetics and Metabolism, Director of the Rare Disease Institute and the Margaret O’Malley Chair of Genetic Medicine at Children’s National Hospital, Emeritus Professor of Pediatrics at George Washington University. Dr. Summar is an internationally recognized expert in urea cycle disorders (UCDs) with over four decades of clinical, research, and policy leadership.
Virtual Presentation: Wednesday, September 23, 2026, at 4:30 p.m. ET
- Domestic: 1-800-347-6865
- International: 1-203-518-9757
- Conference ID: Arcturus
- Webcast: Link
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.